20.04.2018
BB BIOTECH AG CH0038389992
DGAP-Adhoc: BB Biotech share gains value in first quarter 2018 - several large-cap biotech companies trading at well below fundamental value
DGAP-Ad-hoc: BB BIOTECH AG / Key word(s): Quarter Results
BB Biotech share gains value in first quarter 2018 - several large-cap
biotech companies trading at well below fundamental value
20-Apr-2018 / 07:00 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation
(EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Media release as of April 20, 2018
Interim report of BB Biotech AG as of March 31, 2018
BB Biotech share gains value in first quarter 2018 - several large-cap
biotech companies trading at well below fundamental value
Volatility has returned to the markets, staging a revival in the first
quarter of 2018. Regardless of the cautious investor sentiment, the BB
Biotech share performed very well with an overall return (including
dividend) of 8.8% in CHF and 7.3% in EUR. The portfolio trended sideways on
the market, generating a profit of CHF 28 mn (CHF 375 mn in the
corresponding period of the previous year). At the AGM on March 13, 2018,
the Board of Directors confirmed the continuation of the payout policy. A
number of portfolio companies - including Novo Nordisk, Neurocrines Partner
Abbvie, Esperion, Alexion and Alder - published encouraging study results.
Several large biotech companies are currently trading at well below their
fundamental value, with pipeline successes and additional takeovers likely
to boost key ratios and valuations.
Equity markets got off to a volatile start in 2018. The 2017 rally extended
briefly into the first quarter 2018 but reversed by February as US fiscal
policy tightened followed and faltered again in March as US and China trade
wars loomed. For the quarter, the S&P 500 held steady with a negative 0.8%
return, the Dow Jones lost 2.0% and the Nasdaq Composite Index gained 2.6%
(all values as total returns in USD). In contrast to the US which was buoyed
by a weakening US dollar, European market indices declined including Euro
Stoxx 600, which was down 4.0%, the DAX index was down 6.4% in EUR, and the
SPI was down 5.2% in CHF.
Healthcare followed broader US equity indices. The drug space was subject to
speculative discussions about lower drug pricing. New ideas, such as payers
sharing rebates with patients and more debate about value-based pricing
continue to fuel intermittent anxieties about drug and other healthcare
sub-sector stocks. The MSCI World Healthcare Index (-1.0%) and the Nasdaq
Biotechnology Index (0.1%) traded sideways (all values in USD).
BB Biotech's performance for the first quarter 2018
Despite these headwinds, BB Biotech shares gained 8.8% in CHF and 7.3% in
EUR in the first quarter 2018. The portfolio was essentially flat at +0.4%
in CHF, -0.1% in EUR and +2.3% in USD. The net profit amounted to CHF 28 mn
compared to a net profit of CHF 375 mn for the same period in 2017. The
currency impact was -1.9% as the US dollar declined modestly against the
Swiss Franc. Return calculations for BB Biotech take into account the
dividend distribution approved by shareholders at the AGM on March 13, 2018.
Continued capital distribution
BB Biotech paid out that proposed dividend of CHF 3.30 per share. The Board
confirmed the continuation of the dividend policy and anticipates pay out of
a regular dividend of 5% of the prior December's average share price.
The eleventh share repurchase program, started in April 2016, which allows
BB Biotech to acquire up to 10% of the company's outstanding shares over a
period of up to three years, continues. BB Biotech did not trade on the
second trading line in the first quarter of 2018, which means it has not
been used since April 2016.
Increase of investment levels in the first three months of 2018
The management team increased short-term credits - increasing investment
levels from 102.5% to 108.7% during the quarter. And in total, the dividend
payout of CHF 183 mn plus investments in promising new and existing
portfolio holdings modestly exceeded cash received from sale of Juno shares
to Celgene which generated USD 164 mn of cash inflow for BB Biotech.
First quarter portfolio activity
As always, existing portfolio positions were carefully adjusted amid choppy
equity markets. BB Biotech re-invested profits from holdings in Agios,
Neurocrine, Sage, Alnylam and Gilead into firms which offered attractive
re-entry levels such as Tesaro, Ionis and Regeneron and built further stakes
in Akcea Therapeutics and Voyager Therapeutics.
Continuing the strategy of investing in innovative smaller and mid-cap
companies, Moderna Therapeutics, a private company which is pioneering a new
class mRNA medicine, has been added to the portfolio. Their pipeline
includes candidates for vaccines and treatments in diverse therapeutic
areas. Moderna has ten clinical trials underway and has so far raised more
than USD 1.5 bn in equity and USD 1 bn in smart strategic deals. BB Biotech
invested USD 70 mn into Moderna's Series G, broadening our RNA technology
exposure which reached 19% of the portfolio by the end of the first quarter.
A second new portfolio position was initiated with Argenx being an antibody
platform company with a range of mid-to-late stage clinical candidates -
ARGX-113 being the most advanced. This molecule is being studied in three
IgG-mediated autoimmune diseases. Important clinical trial read-outs are
expected in the coming 12 months. A second candidate, ARGX-110, should begin
proof-of-concept clinical trials for acute myeloid leukemia later in 2018.
Solid progress of the portfolio holdings
BB Biotech also saw key late-stage clinical trials data during the first
quarter of 2018. Novo Nordisk reported positive results from the Phase III,
PIONEER-1 trial of orally available semaglutide for type 2 diabetes. Oral
semaglutide improved HbA1c (long-term blood sugar) at all dose levels
tested. The highest dose also caused impressive weight loss (>4 kg at 26
weeks). Novo Nordisk expect to report nine more trials for oral semaglutide
in 2018 and to file for approval in 2019. Once approved, oral semaglutide
will allow Novo Nordisk to target a large and fast growing market segment.
Alder reported a second positive Phase III trial, PROMISE 2, for eptinezumab
in chronic migraine prevention. One third of patients achieved at least 75%
reduction of migraine days compared to baseline. About 15% of patients had
no migraines for three months. If approved, Alder is expected to launch
eptinezumab in 2019.
Alexion's late stage development candidate ALXN-1210 for complement
inhibition in PNH patients was tested successfully. ALXN-1210 given every
two months is similar in effect to Soliris given every two weeks for key
endpoints such as transfusion avoidance and lactate dehydrogenase
normalization. These data support a potentially attractive life-cycle
extension play for Alexion as they intend to submit regulatory applications
in the US, EU and Japan in the second half of 2018.
Neurocrine's partner Abbvie announced two positive Phase III studies, ELARIS
UF-I and -II, for elagolix. In combination with low-dose hormone (add-back)
therapy, elagolix reduced heavy menstrual bleeding in around 75% of women
compared to around 10% in the placebo group. Abbvie expects to secure US FDA
approval for the treatment of endometriosis in the third quarter of 2018 and
will submit another application for uterine fibroids in 2019.
Esperion's STUDY 4 of bempedoic acid met its primary endpoint - lowering
LDL-C by 24% in patients on either ezetimibe or low dose statin. The company
is expected to report four additional Phase III studies in 2018 and submit a
new drug application in early 2019.
Two of BB Biotech's portfolio companies scored FDA approvals in Q1 2018.
Gilead won approval for Bictarvy, a triple combination HIV pill. Vertex won
approval of Symdeko - their third cystic fibrosis drug - this one for
patients >12 years old with homozygous or heterozygous F508del mutation.
The management team was disappointed to learn that Celgene got a surprise
refusal-to-file letter from the FDA for ozanimod in relapsing multiple
sclerosis. Also, Radius got a negative vote from the EMA for
Abaloparatide-sc for treating osteoporosis in postmenopausal women.
Despite some Wall Street expectations, M&A activities have not accelerated
yet - even in the wake of cash repatriation and tax reform. BB Biotech
continues to enjoy and anticipates attractive exits such as Kite - sold to
Gilead for USD 12 bn in 2017, and Juno - sold to Celgene for USD 9 bn in
January 2018 - realizing a net profit for BB Biotech of USD 96 mn. With this
transaction, both BB Biotech holdings focusing on cell-based therapies were
taken over by large cap biotechnology companies.
Outlook
Important milestones are expected in biotech for 2018 - and the management
team believes these will overcome the shortterm downturn in sentiment seen
in the first quarter. Several large cap biotechnology companies currently
trade well below fundamental value, so we expect pipeline successes and more
takeovers to drive multiples and valuations higher.
In a highly anticipated study, Incyte reported that Epacadostat, tested in
combination with Keytruda in patients with unresectable or metastatic
melanoma, did not add benefit over Keytruda monotherapy. However, BB Biotech
assumes that investor's attention will shift towards the company's remaining
broad pipeline. For the rest of the year, further late stage clinical trial
results and product approvals are expected to drive equity value. In
addition, the management team anticipates M&A activities will continue.
Pharmaceutical and large biotechnology companies have stated real interest
in acquisition of leading technologies.
The US healthcare system - now largely influenced by the leadership of Alex
Azar (HHS) and Scott Gottlieb (FDA) - will move towards improved price
transparency driving changes in the somewhat testy relationships between
payers, PBMs, providers and the drug industry. BB Biotech's longstanding
commitment to invest in leading technologies, addressing unmet medical needs
with sustainable economic value continues to underpin its strong and
optimistic commitment to the sector. The management team will continue to
add promising new smaller and mid-cap positions to the investment portfolio
and manage the portfolio actively to produce the best results for the
shareholders.
The complete interim report as at March 31, 2018 is available on
www.bbbiotech.com
For further information:
Investor Relations
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland,
tel. +41 44 267 67 00
Dr. Silvia Schanz, [email protected]
Maria-Grazia Iten-Alderuccio, [email protected]
Claude Mikkelsen, [email protected]
Media Relations
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland,
tel. +41 44 267 67 00
Tanja Chicherio, [email protected]
TE Communications AG, Bleichestrasse 11, 9000 St. Gallen, Switzerland, tel.
+41 79 423 22 28
Thomas Egger, [email protected]
www.bbbiotech.com
Company profile
BB Biotech invests in companies in the fast growing market of biotechnology
and is one of the world's largest investors in this sector. BB Biotech is
listed in Switzerland, Germany and Italy. Its investments are focused on
listed companies that are developing and commercializing novel medical
treatments and cures. BB Biotech's investment selection process is guided by
the fundamental research and analysis of physicians and molecular
biologists. Its Board of Directors has many years of experience in industry
and science.
Disclaimer
This release contains forward-looking statements and expectations as well as
assessments, beliefs and assumptions. Such statements are based on the
current expectations of BB Biotech, its directors and officers, and are,
therefore, subject to risks and uncertainties that may change over time. As
actual developments may significantly differ, BB Biotech and its directors
and officers accept no responsibility in that regard. All forward-looking
statements included in this release are made only as of the date of this
release and BB Biotech and its directors and officers assume no obligation
to update any forward-looking statements as a result of new information,
future events or other factors.
Composition of BB Biotech's portfolio as of March 31, 2018
(in % of securities, rounded values)
Ionis Pharmaceuticals 9.8%
Incyte 8.0%
Celgene 7.7%
Neurocrine Biosciences 7.3%
Vertex Pharmaceuticals 6.3%
Radius Health 5.5%
Agios Pharmaceuticals 5.4%
Gilead 5.2%
Esperion Therapeutics 4.5%
Halozyme Therapeutics 4.3%
Sage Therapeutics 4.2%
Alexion Pharmaceuticals 4.0%
Novo Nordisk 3.6%
Alnylam Pharmaceuticals 3.1%
Regeneron Pharmaceuticals 2.5%
Tesaro 2.4%
Myovant Sciences 1.9%
Moderna Therapeutics 1) 1.8%
Macrogenics 1.7%
Akcea Therapeutics 1.6%
Avexis 1.3%
Intra-Cellular Therapies 1.2%
Voyager Therapeutics 1.0%
Wave Life Sciences 0.9%
Intercept Pharmaceuticals 0.9%
Argenx SE 0.8%
Alder Biopharmaceuticals 0.7%
Novavax 0.5%
Five Prime Therapeutics 0.4%
Prothena Corp. 0.4%
Probiodrug 0.4%
Cidara Therapeutics 0.2%
Achillion Pharmaceuticals 0.1%
Idorsia 0.1%
Radius Health Warrants, 04/23/2018 0.1%
Radius Health Warrants, 02/19/2019 <0.1%
Total securities CHF 3 679.8 mn
Other assets CHF 9.3 mn
Other payables CHF (305.0) mn
Net asset value CHF 3 384.1 mn
1) Unlisted company
---------------------------------------------------------------------------
20-Apr-2018 CET/CEST The DGAP Distribution Services include Regulatory
Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: BB BIOTECH AG
Schwertstrasse 6
8200 Schaffhausen
Switzerland
Phone: +41 52 624 08 45
E-mail: [email protected]
Internet: www.bbbiotech.ch
ISIN: CH0038389992
WKN: A0NFN3
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart; SIX
End of Announcement DGAP News Service
---------------------------------------------------------------------------
676601 20-Apr-2018 CET/CEST
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
BB BIOTECH AG ISIN: CH0038389992 können Sie bei EQS abrufen
Biotechnologie , A0NFN3 , BBZA , XETR:BBZA